HER2+ Breast Cancer - priME Oncology
Webcast
Webcast

HER2+ Breast Cancer

Closing the Gaps in Current Treatment

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Get the latest updates in HER2+ breast cancer with this webcast from our EBCC symposium. A variety of topics are discussed, including challenges in the management of HER2+ breast cancer, new and emerging agents in both the adjuvant and metastatic settings, and unmet medical needs.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Apr 23, 2018

Expiration Date

May 1, 2019

HER2+ breast cancer: Remaining challenges after 20 years of trastuzumab
Suzette Delaloge, MD, MSc

Adjuvant treatment for HER2+ breast cancer: When is trastuzumab not enough?
Wolfgang Janni, MD, PhD

Metastatic HER2+ breast cancer: The search for further treatment improvements
Pierfranco Conte, MD

prIME Points™
Sibylle Loibl, MD, PhD

  • Pierfranco Conte, MDIstituto Oncologico Veneto
    University of Padua
    Padua, Italy
  • Suzette Delaloge, MD, MScGustave Roussy
    Villejuif, France
  • Wolfgang Janni, MD, PhDUniversity of Ulm
    Ulm, Germany
  • Sibylle Loibl, MD, PhDGerman Breast Group, Neu-Isenburg
    Centre for Haematology and Oncology Bethanien
    Frankfurt, Germany

This educational activity is specifically designed for oncologists and other healthcare professionals interested in and/or involved in the treatment of breast cancer who wish to understand some of the latest developments in treatments for patients with HER2+ breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
  • Select the optimal HER2-targeted strategies to improve outcomes for patients with HER2+ breast cancer in the early and metastatic settings
  • Assess new and emerging treatment options for patients with metastatic HER2+ breast cancer

This educational activity is supported by a grant from Puma Biotechnology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Conte has disclosed that he has received consulting fees from Celgene. He was contracted independently by Merck Serono, Novartis, and Roche. He has also received speaking and teaching fees from AstraZeneca, GlaxoSmithKline, Novartis, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Delaloge has disclosed that she has received consulting fees from AstraZeneca, Lilly, Pfizer, and Roche. She has disclosed independent contracting for Amgen, AstraZeneca, Lilly, Novartis, Pfizer, Puma Biotechnology, Roche, and Sanofi. She has also completed speaking and teaching engagements for AstraZeneca, Pfizer, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Janni has disclosed receipt of fees for consulting and membership on an advisory committee or review panel from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Loibl has disclosed that her institution received honoraria and research funding from Amgen, AstraZeneca, Celgene, Novartis, Pfizer, Roche, Teva, and Vifor. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – contracted research for or research support from Amgen and Bayer
  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.